Objective: Sugar consumption has increased markedly over the last few decades and parallels the dramatic increase in overweight and obesity. Data obtained from animal studies suggest that the intestinal serotonergic system and herein particularly the serotonin receptor 3 (5-HT3R) may be involved in sugar detection and short-term control of food intake. Using a mouse model, we tested the hypothesis that blocking 5-HT3R prevents the development of sugar-induced obesity. Design: For 8 weeks, C57BL/J6 mice were offered either water containing 30% glucose or plain water in addition to normal chow. The effect of oral treatment with the 5-HT3R antagonist, tropisetron (0.2 mg kg À1 body weight), on body weight and caloric intake was studied. Results: Total caloric intake and weight gain were significantly increased in mice fed glucose compared with the control group. Tropisetron treatment reduced intestinal motility and almost completely blocked weight gain associated with glucose feeding; however, total caloric intake was not affected. The effect of tropisetron was not associated with a decreased expression of the intestinal and hepatic glucose transporters, SGLT1 (sodium-dependent glucose cotransporter) and Glut2 (glucose transporter 2); instead, the expression of these transporters was slightly increased by the 5-HT3R antagonist. However, expressions of carbohydrate responsive element binding protein and fatty acid synthase, as well as triglyceride levels in the liver were only enhanced in mice fed glucose, but remained unchanged at the level of the control group when mice were treated concomitantly with tropisetron. At the same time, b-hydroxybutyrate dehydrogenase mRNA expression and plasma levels of ketone bodies were significantly increased. Conclusion: Our results suggest that 5-HT3R is a new target for the modulation of hepatic glucose metabolism and for the prevention of obesity.
Introduction
The prevalence of overweight and obesity has increased dramatically worldwide over the last few decades. Overweight and obesity have been identified as key risk factors for chronic diseases, such as cardiovascular diseases, type 2 diabetes, lipid disorders and nonalcoholic fatty liver disease (for a review, see Olufadi and Byrne 1 ). The causes of obesity are numerous and complex, and generally accepted strategies used to prevent or treat obesity in humans are still limited. Therefore, a better understanding of the biochemical and pathological mechanisms that lead to obesity is mandatory to improve the outcome of interventions.
High dietary fat intake has long been believed to be the major cause of obesity (for a review, see Astrup 2 ); however, other factors may also contribute to it. For instance, the intake of carbohydrates, and herein particularly monosaccharides and disaccharides (such as glucose, fructose and sucrose), has increased dramatically over the last three decades. In particular, a high consumption of sweetened soft drinks is associated with the prevalence of obesity and type 2 diabetes in the United States. 3, 4 Most soft drinks are sweetened with sugars such as sucrose or high fructose corn syrup, both containing fructose and glucose. The hypothesis that sugar-sweetened drinks, and herein particularly glucose, may contribute to the development of obesity is supported by the results of human and animals studies. Indeed, Spitzer and Rodin 5 found food intake to be increased in humans after a preload with glucose solution, whereas fructose solution had no such effect. Furthermore, Brito et al., 6 Lindqvist et al. 7 and our own group 8 found that a chronic intake of glucose-sweetened drinking water, results in a significant increase in total caloric intake, body weight and abdominal fat index in rodents. Sclafani 9 reported a body weight gain, increased total caloric intake and a reduced chow intake in rats fed a 32% glucose solution in comparison with rats fed 32% glucose powder. However, mechanisms involved in the excessive intake of glucose and the subsequent increase in total calories and weight gain have not been clarified. The serotonergic system has been studied to some extent for its role in the control of food intake. For instance, the administration of agonists that activate the postsynaptic serotonin (5-HT) receptors has been shown to produce a marked reduction in food intake. [10] [11] [12] Serotonin receptor 3
(5-HT3R) is involved in the regulation of major digestive functions, such as gastric emptying and pancreatic secretion, 13, 14 as well as in the control of food intake under several feeding paradigms. For instance, 5-HT3R mediates intestinal Polycose (glucose polymersFeasily digested source of carbohydrate calories) and glucose-induced suppression of food intake in short-term intraduodenal feeding models. 15 Furthermore, lipid-induced satiation seems to depend on 5-HT3R 16 too. Moreover, intestinal 5-HT3R is also involved in the nodose neuronal response to luminal digestion products of carbohydrates (for example, glucose) further suggesting that intestinal 5-HT3R may participate in the control of food intake. 14, 15 However, whether 5-HT3R in the intestine also modulates the effects of sugar-sweetened beverages in a chronic setting and subsequently may be involved in the development of obesity has not been clarified. Using a mouse model of high glucose feeding to induce obesity, we investigated whether 5-HT3R may contribute to the development of glucose-induced obesity.
Materials and methods

Animals and treatments
Mice were housed in a pathogen-free barrier facility accredited by the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care). All procedures were approved by the local IACUC (Institutional Animal Care and Use Committee). Eight-week-old C57BL/J6 mice were obtained from Janvier (Le-Genes-St-isle, France). In total, data obtained from 28 animals divided on a random basis into 4 treatment groups with 7 animals in each were included in the study. Animals from the control group without any treatment (C) had free access to standard chow (ssniff M-Z Ereich; ssniff Spezialdiäten GmbH, Soest, Germany), and plain water during the 8-week feeding period.
Animals from the control group with tropisetron treatment (C þ T) had identical conditions to the control animals, except that their water was supplemented with tropisetron. Animals of the third group (G) had free access to chow containing higher amounts of protein, essential amino acids, vitamins and minerals (modified ssniff M-Z Ereich (percentage of calories from protein 32%, carbohydrates 48% and fat 20%); ssniff Spezialdiäten GmbH), and water containing 30% glucose as the only drinking solution. Animals of the fourth group (G þ T) had identical conditions to animals of the third group, except that glucose water was supplemented with tropisetron. Enriched chow was used for animals fed glucose solution, because we showed previously that adding glucose to drinking water causes a reduction in caloric intake from chow. 8 Liquid intake was assessed thrice a week, whereas chow intake and body weight were assessed weekly. Tropisetron (Navoban, Novartis Pharm., Basel, Switzerland) was administered in a daily concentration of 0.2 mg kg À1 body weight, and concentration was adjusted weekly according to weight gain and liquid intake of animals. Small intestinal motility was measured as described previously. 17 Briefly, all animals received an intragastric bolus dose of a charcoal solution (charcoal 0.5 g, arabigum 0.25 g and NaCl (0.9%) 5 ml) by gavage 10 min before euthanization. Five minutes later, the animals were anesthetized with 80 mg ketamine and 6 mg xylazine per kg body weight intraperitoneally. After opening the abdominal cavity, blood was collected and the migration distance of the charcoal solution in the small intestine was determined using a ruler. Portions of the small intestine (duodenum and ileum) and liver tissue were frozen immediately in liquid nitrogen, whereas other samples were frozen-fixed in Tissue Tek O.C.T. Compound mounting media (Medite, Burgdorf, Germany).
RNA isolation and real-time reverse transcriptase-PCR Total RNA was extracted from the small intestine and liver tissue samples using Trizol Reagent (Invitrogen Corp., Karlsruhe, Germany). RNA concentrations were determined spectrophotometrically, and 1 mg of total RNA was reverse transcribed using a Murine Leukemia Virus (MuLV) reverse transcriptase and oligo dT primers, followed by a DNase digestion step (Fermentas, St Leon-Rot, Germany 
Liver triglycerides
Portions of the mouse liver tissue were homogenized in icecold 2 Â phosphate-buffered saline. Tissue lipids were extracted with methanol/chloroform (1:2), dried and resuspended in 5% fat-free bovine serum albumin. Colorimetric assessment of triglyceride levels was carried out using a commercially available kit (Randox, Krefeld, Germany).
Values were normalized to the protein concentration in the liver homogenate before extraction using the Bradford assay (Bio-Rad Laboratories).
Immunohistochemical staining of serotonin
For detection of serotonin-positive cells in the small intestine, tissue sections were incubated with a peroxidase-linked secondary antibody and diaminobenzidine (Peroxidase Envision Kit; DAKO, Hamburg, Germany). This resulted in the sought after cells being stained brown. To ensure specificity of serotonin staining (Sigma, Steinheim, Germany; 1:5000 in TBST (Tris-buffered saline þ 0.1% Tween)), the following controls were used: (1) omission of the primary antibody, (2) omission of the horseradish peroxidase-labeled secondary antibody, (3) omission of the EnVision complex, (4) omission of the primary and secondary antibodies, as well as the EnVision complex, (5) omission of the primary and secondary antibodies and (6) the omission of the secondary antibody and the EnVision complex. The numbers of 5-HT-positive cells in the small intestine were counted in 10 randomly selected fields using a Zeiss microscope (Axio Vert 200M) (Zeiss, Jena, Germany) with the magnification of Â 400. b-Hydroxybutyrate concentration in plasma b-Hydroxybutyrate was measured in the plasma using a commercially available kit according to the manufacture's instructions (Randox).
Statistical analyses
Results are reported as means ± s.e.m. Results from the four treatment groups were compared by analysis of variance (ANOVA). Before performing ANOVA, data were tested for homogenous variances using the Bartlett test. Only if the homogeneity of variances was confirmed, ANOVA was performed. Statistically significant differences between the groups were considered if ANOVA yielded a Po0.05. In this case, we additionally performed Tukey's post hoc test to identify the individual differences between the means. In the figures and tables, the results of Tukey's test are indicated. No Tukey's test was conducted, if ANOVA was not significant. The SPSS software package, release 18.0 (SPSS, Chicago, IL, USA), was used.
Statement of ethics
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Results
Effect of glucose-sweetened water and concomitant tropisetron treatment on body weight, liquid intake, food consumption, total energy intake and intestinal motility Average body weight gain and energy intake, mean body weight at the start and end of the feeding period, liquid and chow intake, as well as the measurement of intestinal motility, are summarized in Figure 1 and Table 2 . Chow intake was reduced by B60% in mice fed glucose solutions regardless of additional tropisetron treatment. However, as glucose-fed mice drank significantly more liquid ( þ B30% in comparison with the control group, (Pp0.01)), total caloric intake was significantly higher ( þ 30% per week, (Pp0.01)) in these groups compared with the control groups, which were offered only plain water. As expected, animals fed glucose-supplemented water gained significantly more weight than did control mice fed normal water (Pp0.001). However, an increased body weight gain was not observed in mice fed water supplemented with glucose and tropisetron despite the fact that the caloric intake was similar in both TCC CGT CCT ACG AG  CAA TCG GCC ACC ACA CCA TA  Glut2  ACT GGA AGC AGA GGG CGA TG  CAT GTC GGT GGG ACT TGT GC  FAS  TCT GGG CCA ACC TCA TTG GT  GAA GCT GGG GGT CCA TTG TG  ChREBP  CTG GAC CGA CCC CTC TCC TT  TTG TGG GTG CAG GAA GCG TA  Bdh1  GAA TTC AGC CTG CCG GTT TG  TGC ATC CCG CTG TCA GGT Obesity prevention by 5-HT3 receptor blockage S Weber et al glucose-fed animal groups. Rather, no weight difference could be observed between mice fed water supplemented with glucose and tropisetron and mice in the control groups. Interestingly, abdominal fat pads have only been observed in glucose-treated animals. These fat pads were reduced in animals concomitantly treated with tropisetron; however, these changes have not been quantified (data not shown). The effect on intestinal motility was determined by the migration of the charcoal solution from the pylorus into the intestine. Intestinal motility did not differ between plain water controls and plain water controls concomitantly treated with tropisetron. In contrast, intestinal motility was significantly enhanced in mice fed a 30% glucose solution ( þ 53% in comparison with the control group, (Pp0.01)). Interestingly, when mice were treated concomitantly with tropisetron while being fed a 30% glucose solution, intestinal motility was reduced to the level of the control group.
Effect of glucose-sweetened water and concomitant tropisetron treatment on the number of 5-HT-positive cells in the small intestine To determine whether the decreased weight gain of glucosefed mice was associated with tropisetron treatment and might affect the intestinal serotonergic system, we estimated the number of 5-HT-positive cells in the duodenum. Glucose feeding over 8 weeks led to a significant increase in the number of 5-HT-positive cells in the mucosal layer ( Figure 2 ) ( þ B65% in comparison with the control group; Pp0.05). However, concomitant treatment of animals with tropisetron did not change the number of 5-HT-positive cells in the duodenum. All staining controls as described in the 'Materials and methods' section were negative (data not shown). A similar effect on the number of 5-HT-positive cells after glucose feeding was not found in the ileum (data not shown).
Effect of glucose-sweetened water and tropisetron treatment on glucose transporter expression in the small intestine and liver To test whether the protective effect of tropisetron was associated with a decrease in glucose transporters, we determined the mRNA expression of the two main transporters, SGLT1 and Glut2, involved in glucose uptake in the small intestine and liver, respectively (Figure 3 ). The expression of SGLT1 and Glut2 in the duodenum did not differ between control groups fed plain water, with or without tropisetron, or mice fed water enriched with 30% Effect of glucose-sweetened water and tropisetron treatment on glucose metabolism and triglyceride accumulation in the liver To determine whether alterations in the metabolism of glucose in the liver were involved in the protective effects of tropisetron, we determined expression levels of ChREBP and FAS in the liver and measured hepatic triglyceride levels ( Figure 4) . The expression of hepatic ChREBP did not differ between control groups. As expected, the expression levels of ChREBP mRNA in the livers of mice fed water enriched with 30% glucose were significantly induced by B1.5-fold compared with the plain water control group (Pp0.05). Interestingly, tropisetron prevented this induction almost completely. Similar results were also found for the hepatic FAS mRNA expression; however, differences between treatments were even more striking (Pp0.05). Interestingly, the effects on hepatic triglyceride levels were parallel to the mRNA data. In mice fed a 30% glucose solution, the levels of hepatic triglycerides were increased B2.8-fold in comparison with the plain water control group (Pp0.001). Concomitant treatment of animals with tropisetron almost completely protected mice from glucose-induced lipid accumulation in the liver.
Effect of glucose-sweetened water and tropisetron treatment on the hepatic expression of b-hydroxybutyrate dehydrogenase (Bdh1) and 3-hydroxybutyrate plasma levels A possible explanation for the protective effect of tropisetron against the enhanced hepatic lipid accumulation found in glucose-fed mice could be that tropisetron treatment provoked a metabolic shift in the liver of mice fed glucose from a more anabolic to a more catabolic stage. To test this possibility, we determined the expression levels of 3-hydroxybutyrate dehydrogenase 1 (Bdh1) mRNA in the liver tissue and the concentration of 3-hydroxybutyrate in the plasma of animals ( Figure 5 ). Expression of hepatic Bdh1 did not differ between the two control groups and the group fed plain glucose solution; however, in the livers of animals fed a 30% glucose solution and treated with tropisetron expression of Bdh1 was significantly increased 1.6-1.7-fold in comparison with the control groups (Pp0.01). In accordance with these findings, the plasma concentration of 3-hydroxybutyrate was approximately fivefold higher in mice fed a glucose solution with tropisetron in comparison with all other groups (Pp0.01). However, tropisetron had no effect on plasma 3-hydroxybutyrate levels in mice fed water.
Discussion
Carbohydrates and herein particularly monosaccharides and disaccharides such as glucose and sucrose have a central role in the etiology of obesity as shown in human and animal studies. [18] [19] [20] Using animal models, novel insights have been Obesity prevention by 5-HT3 receptor blockage S Weber et al obesity. For example, these studies showed that high glucose consumption causes an increase in body weight and abdominal fat associated with an increased protein oxidation induced by hyperglycemia, and that carbohydrate-induced obesity is not dependent on the sweet taste of carbohydrates. 6, 21, 22 Another important mechanism through which the intake of carbohydrates and particularly a glucose intake may be regulated is through a modulation of the intestinal serotonergic system. Indeed, previous studies have indicated that intestinal 5-HT3R might be involved in the detection and control of carbohydrate intake, such as glucose. 14, 15 In this study, we have extended these findings by showing for the first time that intestinal 5-HT3R contributes to the development of glucose-induced obesity in mice. Using a mouse model of high glucose feeding through ad libitum access to water enriched with glucose, we have shown that glucose exposure changes eating habits and bowel functions. A chronic intake of 30% glucose in a drinking solution resulted in a marked decrease of chow intake in comparison with the control group; however, as mice exposed to glucose solutions drank significantly more, total caloric intake and weight gain were significantly increased in these animals. This increased intake of calories led to an increased body weight, enhanced triglyceride content in the liver and was associated with an increase in intestinal motility. Most interestingly, glucose exposure led to an increased number of 5-HT-positive cells in the duodenum.
Oral treatment with tropisetron neither affected liquid nor chow intake of the mice. This finding was independent of whether mice received plain water or glucose-containing water. Similar results were found by Savastano et al. 15 who found no change in caloric intake by 5-HT3 blockage; however, this group described more rapid chow intake in glucose-fed animals contrasting our results. Our results further show that small intestinal motility was enhanced in animals fed glucose; however, the concomitant treatment with tropisetron slowed down motility to the level of the control group. On the other hand, increase in the number of 5-HT-positive cells found in the duodenum of glucose-fed mice was not affected by tropisetron treatment. It is most interesting that, despite the similar caloric intake of animals fed glucose with or without tropisetron, tropisetron-treated animals gained markedly less weight than did mice fed only glucose. Thus, tropisetron prevents weight gain in animals fed glucose through drinking water. Some publications suggest that 5-HT3 receptor antagonists might enhance physical activity in rats. 23, 24 However, the findings derive from particular models that are not easily comparable with our experimental setting. Moreover, these studies did not address body weight changes. We did not measure physical activity in our studies. On the other hand, we found no changes in food or caloric intake between the groups of animals that received tropisetron or those that did not, independent of whether normal or glucose-rich water was offered. Finally, we did not detect a reduced body weight in the control group treated with tropisetron, which might indicate an increased energy expenditure or physical activity. Eating behavior, appetite, satiety and thus control of body weight are influenced by the serotonergic system. For example, selective serotonin-reuptake transporter inhibitors including citalopram, fluxetin and sertraline are useful tools for attempting to reduce body weight in rodent models 25, 26 and obese patients. 27 Apart from inhibitors of the serotoninreuptake transporter, inhibitors of the serotonin receptors 5-HT1b and 5-HT2c were found to be effective in weight reduction 28, 29 and even more effective in combination with serotonin-reuptake transporter inhibitors. 30 Moreover, our data clearly show that the 5-HT3 receptor is involved. However, the mechanisms by which 5-HT3-receptor blockage affects body weight are unclear at present. Our present data provide evidence for peripheral effects such as changes Obesity prevention by 5-HT3 receptor blockage S Weber et al in glucose transporter expression in the intestine and liver, or changes in gastrointestinal motility; however, we did not conduct studies at the level of the central nervous system. Indeed, others have shown that tropisetron passes the blood-brain barrier and exerts multiple effects in the central nervous system, possibly also weight control effects. 31 On the other hand, central effects of tropisetron with regard to weight change, appetite control or obesity have not been reported. Our data, together with previous publications, suggest that a suppression of the serotonergic system in the intestine may result in alterations of food intake and weight regulation. The main difference between previous studies and our study is that we did not see a reduction or increase in the food intake by blockage of 5-HT3R. In contrast, Savastano et al. 15 showed that ondansetron, another 5-HT3R antagonist, attenuated the glucose-induced, serotonin-mediated suppression of food intake in a food-deprived rat model. The reason for such discrepancies may be the different methodological approaches between our study and those by Savastano. Savastano et al. investigated the effects of inhibiting 5-HT3R on food intake in short-term settings in which rats were fed only once with glucose administered through a duodenal catheter and the effects were studied over a time period of 60 min. Savastano et al. examined the effect of ondansetron on glucose-induced inhibition of sucrose (not glucose) intake, but they did not analyze weight gain. Moreover, they studied food-deprived rats, whereas we examined mice that had an ad libitum access to glucose in our studies. Taken together, our results indicate that the 5-HT3R antagonist tropisetron does not alter total caloric intake in the described experimental setup, but it protects against glucose-induced obesity by mechanisms independent of caloric intake.
To test the hypothesis that tropisetron changes glucose uptake in the intestine or liver, we studied expression levels of the two main glucose transporters, SGLT1 and Glut2. The expression of both transporters in the duodenum was not changed by glucose but was significantly increased in glucose-fed mice treated with tropisetron. Furthermore, we found a similar effect of tropisetron treatment on Glut2 expression in the liver. Kishi et al. 32 also reported no changes in the Glut2 expression in the intestine of rats after 7 days of chronic glucose exposure; however, they found a B50% increase in the SGLT1 expression, which might be the result of the force feeding model used in their experiments. Thus, our results suggest that tropisetron-dependent weight gain protection observed in glucose-fed mice is not a result of decreased glucose uptake in the intestine or liver. Another possibility of how tropisetron might protect mice from glucose-induced weight gain is through the alteration of hepatic glucose metabolism. Recently, it has been reported that glucose activates ChREBP, a carbohydrate responsive element binding protein identified as a key regulator of glucose and lipid metabolism. 33 Specifically, a diet rich in glucose has been shown to activate hepatic ChREBP in animal models leading to an increased expression of enzymes involved in the formation of triglycerides. 34, 35 In this study, we confirmed these results and showed an elevated mRNA expression of ChREBP associated with increased levels of FAS and triglycerides in the liver of mice fed a 30% glucose solution. It is interesting that, such changes were not found in the livers of mice fed glucose concomitantly treated with tropisetron further, suggesting that tropisetron may prevent the metabolism of glucose into triglycerides in the liver. At the same time, we found a significant increase of b-hydroxybutyrate dehydrogenase (Bdh1) expression in the liver, which was associated with increased levels of ketone bodies in plasma in glucose-fed animals concomitantly treated with tropisetron. These data suggest that the protective effects of tropisetron against glucose-induced obesity is mediated, at least in part, by a switch from an anabolic metabolism, in which the excessive intake of glucose results in an enhanced formation of triglycerides and weight gain, to a more catabolic metabolism associated with the formation of ketone bodies.
Apart from the mechanisms discussed in this study, other mechanisms might be involved in the tropisetroninduced prevention of obesity after a high-glucose diet. For example, intestinal 5-HT3R may not only act through direct interaction between the gut and the liver but also through pathways involving a gut-brain axis, or even a gut-liver-brain axis, to modulate glucose and energy metabolism in the body. This hypothesis requires confirmation by further studies.
In conclusion, the results of this study indicate that intestinal 5-HT3R is not only a regulator of intestinal motility but is also a novel regulator of hepatic glucose metabolism. This finding might have important clinical implications, as blocking 5-HT3R using tropisetron protects against glucose-induced obesity and thus the 5-HT3R molecule might become a new target for the therapy of obesity. Such data need confirmation in human trials as previous trials with 5-HT3R antagonists did not analyse systematically weight changes in subgroups of obese and lean individuals.
